Alcami Corporation (“Alcami”), a contract development and manufacturing organization (CDMO), has announced the appointment of pharmaceutical industry veteran Tori E. Arens as president of drug product.

Arens will lead the cGMP drug product manufacturing operations at Alcami, according to a news release. This includes Alcami’s two sterile fill-finish facilities located in Research Triangle Park nd Charleston, South Carolina, and oral solid dose drug product manufacturing, packaging and labeling facilities in Wilmington.

“Tori brings a unique skillset of manufacturing expertise along with strong leadership skills, that will be of great value to Alcami, our customers and their patients alike,” stated Patrick Walsh, Alcami chairman and interim CEO, in the release.

Arens has more than 25 years of experience in the development, technology transfer, manufacture and supply of drug substance and sterile drug products supporting small molecules, biologics and gene therapies, according to the release. She most recently served as vice president, general manager and site head for Resilience’s RTP facility for gene therapy viral vector manufacturing.

Her previous responsibilities include vice president, drug product manufacturing and supply, at Aerie Pharmaceuticals (now Alcon), director of parenteral operations at Biogen and senior director of Parenteral Operations at Eisai Inc.

She earned a master's degree in pharmaceutics and bachelor's degree in chemistry from the University of North Carolina Chapel Hill.

Arens stated in the release, “Alcami’s vision, mission, and values deeply resonate with me, and I look forward to leading this area of operations to drive continued success and serve patients worldwide.”